Lab/path equity participation: when buying in actually pays

Group path practices offer buy-in tracks that come with valuations, K-1 income, and a long lock-up. Here’s the framework for evaluating one.

The partnership offer is the holy grail for many early-career pathologists. It’s a validation of your work and a promise of financial upside. But the offer sheet—a dense document of buy-in costs, valuation multiples, and vesting schedules—can feel more like a puzzle than a prize. Most of us get fixated on the top-line valuation number, but the real value is often buried in the tax structure and ancillary ownership opportunities. The difference between a good buy-in and a great one isn’t just the multiple on EBITDA; it’s whether the partnership is structured to maximize after-tax, take-home cash for its partners. Understanding these structures is critical. For a deeper dive into the specialty’s operational landscape, you can explore our full pathology resources hub. This article breaks down the key financial levers that determine if buying in will actually pay off.

The Core Economics: Owning the Outpatient Lab

When I look at a partnership track, the first thing I check isn’t the salary bump. It’s the ownership structure of the group’s assets, particularly any outpatient labs or ancillary services. A hospital-based professional services agreement (PSA) group is one thing, but a group that owns its own technical component (TC) lab is a completely different financial vehicle.

Owning a piece of the lab means you’re no longer just selling your time; you’re an owner of a capital-intensive business. This is where the real wealth generation happens. Your return comes not just from your professional fee collections but from the profits of the lab itself. This income flows to you via a Schedule K-1, which reports your share of the partnership’s income, deductions, and credits. This is fundamentally different from W-2 income.

The magic of K-1 income is its relationship with “paper losses.” A well-structured lab partnership can generate significant non-cash deductions, primarily through depreciation of its expensive equipment and real estate. In the early years of a new lab or after a major equipment purchase, these paper losses can be massive, often offsetting a significant portion of the actual cash distributions you receive. This means you might get a $100,000 cash distribution, but your K-1 shows only $30,000 in taxable income because your share of the depreciation deduction was $70,000.

Here’s the trap: A partnership that doesn’t own its assets can’t offer this. If the group is just a collection of physicians billing for their professional services under a hospital contract, your buy-in is purchasing a share of a future income stream, which is fine, but it lacks the tax-advantaged wealth-building power of asset ownership. You need to ask: What, exactly, am I buying? Is it just goodwill and an accounts receivable, or is it a piece of a tangible, revenue-generating, and depreciable asset like a lab?

Turbocharge Your Deductions: Section 179 & Bonus Depreciation

Pathology labs are built on expensive equipment—digital pathology scanners, high-throughput sequencers, mass spectrometers. This high capital expenditure is a huge financial advantage for the physician-owners, thanks to two powerful provisions in the tax code: Section 179 and bonus depreciation.

Here’s how it works. Normally, when a business buys a large asset, it has to depreciate the cost over several years. But Section 179 allows you to treat the cost of qualifying equipment as an immediate expense in the year it’s placed in service. For 2026, the expensing limit under Section 179 is $1.16 million. This means if your lab buys a new $1 million digital slide scanner, the partnership can deduct the entire $1 million from its income that year.

What if the equipment costs more? That’s where bonus depreciation comes in. After you’ve used your Section 179 deduction, bonus depreciation allows you to immediately deduct a percentage of the remaining cost. While the bonus percentage is phasing down, it remains a powerful tool.

Let’s run a concrete example. Your 10-partner group decides to build out a new molecular diagnostics wing and purchases $2.5 million in new sequencing and analysis equipment.

• Section 179 Deduction: The first $1.16 million is expensed immediately.
• Remaining Basis: $2.5M – $1.16M = $1.34M
• Bonus Depreciation (assuming 60% for 2026): 60% of $1.34M = $804,000.
• Total Year-One Deduction: $1.16M + $804,000 = $1,964,000.

That $1.96 million deduction is passed through to the 10 partners on their K-1s. Each partner gets a $196,400 “paper loss” to shield other practice income from taxes. This is how partners can receive substantial cash distributions while reporting much lower, or even negative, taxable income in the years of heavy investment. This is a critical diligence item when evaluating a buy-in: Does the group have a history of reinvesting in capital equipment, and do the partners benefit from these massive first-year write-offs?

The Building Itself: Unlocking Value with Cost Segregation

If your group owns its lab facility, not just the equipment inside it, there’s another layer of tax efficiency to unlock. Most people assume a commercial building is depreciated straight-line over 39 years. That’s a slow, steady, and relatively small annual deduction. A cost segregation study shatters that assumption.

A cost segregation study is an engineering-based analysis that identifies all the components of your building and reclassifies them from “real property” (39-year life) into “personal property” with much shorter depreciable lives. Think about it: the foundation and structural steel will last for decades, but the carpeting, specialized lab benches, dedicated electrical wiring for equipment, and plumbing are not 39-year assets.

• 5-Year Property: Carpeting, cabinetry, decorative lighting, certain process-related plumbing and electrical.
• 7-Year Property: Lab furniture, data wiring.
• 15-Year Property: Land improvements like parking lots, sidewalks, and landscaping.

A typical study on a medical facility can reclassify 25-30% of the building’s total cost basis into these shorter-lived categories. The impact is enormous. By moving these assets into 5, 7, or 15-year buckets, they become eligible for the same bonus depreciation we discussed for equipment.

Imagine your group builds a new $4 million lab. A cost segregation study might identify $1 million (25%) of that cost as 5- and 15-year property. That $1 million can then be immediately expensed via bonus depreciation in year one. Instead of a small ~$102,000 depreciation deduction (4M/39 years), the partnership gets a deduction of over $1 million in the first year. This creates another massive paper loss that flows to the partners, sheltering income.

When you’re evaluating a buy-in that includes real estate, you need to know if a cost segregation study has been done. If not, it’s a huge potential upside you and your new partners are leaving on the table. The analysis of the real estate component is a core part of the deal’s value. You can use a margin of safety calculator to assess the purchase price of the real estate relative to its intrinsic value, factoring in these powerful tax benefits.

The QBI Workaround: The Equipment Leasing Company

Most physicians are familiar with the Qualified Business Income (QBI) deduction, also known as Section 199A. It allows owners of pass-through businesses to deduct up to 20% of their qualified business income. However, there’s a catch: for high-income earners, physicians are classified as being in a “Specified Service Trade or Business” (SSTB), and the QBI deduction is phased out and eventually eliminated.

This is where sophisticated practice structuring comes in. Many groups have successfully created a workaround by separating their assets from their professional services. The structure looks like this:

1. The Practice (S-Corp or LLC): This is the medical practice itself. It employs the staff, bills for services, and pays the physicians. As an SSTB, its high-earning partners do not get the QBI deduction.
2. The EquipmentCo (LLC): A separate legal entity, owned by the same physicians, is formed to purchase and hold all the expensive lab equipment.
3. The Lease: EquipmentCo then leases the equipment to the Practice at a fair market rate.

The income generated by EquipmentCo—the lease payments it receives from the Practice—is generally *not* considered SSTB income. It’s rental income. This means the net profit from the equipment leasing entity can be eligible for the full 20% QBI deduction, even for high-income physician owners. This strategy effectively converts a portion of non-deductible practice income into QBI-eligible rental income.

There are strict rules to follow. The IRS has specific guidance on this, including aggregation rules under Treasury Regulation §1.199A-4 that require common ownership (50% or more) and other factors. This isn’t a DIY project for a Saturday afternoon; it requires a CPA and attorney who are deeply familiar with these specific regulations. A poorly structured arrangement can be reclassified by the IRS, negating the entire benefit. When evaluating a buy-in, ask if the group uses this structure. Its presence is a strong sign of sophisticated financial management.

For You Personally: The S-Corp and Reasonable Compensation

Finally, let’s talk about your personal structure as a partner. Many partners in pathology groups are not W-2 employees; they are owners who receive distributions of profit. If you structure your professional corporation as an S-corp, you can create another layer of tax savings.

As a self-employed individual or a partner receiving distributions, you’re typically on the hook for self-employment (SE) taxes on all of your net earnings. This consists of 12.4% for Social Security (up to the annual limit, ~$168,600 in 2024) and 2.9% for Medicare (uncapped). That’s a 15.3% tax hit before you even get to federal and state income taxes.

An S-corp allows you to split your income into two categories:

• Reasonable Salary: You must pay yourself a W-2 salary that is “reasonable” for the work you do. This salary is subject to the full FICA taxes (the employee and employer share of SE taxes).
• Distributions: Any profit remaining in the S-corp after paying your salary and other expenses can be paid to you as a distribution. These distributions are *not* subject to FICA or SE taxes.

The savings can be substantial. If your total compensation is $500,000 and you determine a reasonable salary is $300,000, you would take the remaining $200,000 as a distribution. You would save the 2.9% Medicare tax (and potentially the 0.9% additional Medicare tax) on that $200,000, which is a savings of at least $5,800 per year. The key is the “reasonable compensation” analysis. The IRS scrutinizes this, and you can’t just pay yourself a $50,000 salary on $500,000 of income. You need to document how you arrived at your salary figure, using industry benchmarks and data. But for any partner with significant K-1 income, failing to consider an S-corp election is a costly oversight.

A practice buy-in is one of the most significant financial decisions of your career. Looking beyond the surface-level valuation to understand the underlying tax and ownership structure is what separates a decent investment from a truly wealth-generating one. These strategies—asset ownership, accelerated depreciation, and entity structuring—are the engine of partner profitability. If you’re looking at an offer sheet and need help dissecting its true financial implications, you can request a diligence memo on a buy-in to get an independent analysis of the deal’s structure and hidden value.

Free GigHz Tools That Pair With This Article

Three free tools that complement the material above:

• ACR Appropriateness Criteria Lookup — Type an indication or clinical scenario in plain language and get the imaging studies the ACR rates for it, with adult and pediatric radiation levels. Built directly from 297 ACR topics, 1,336 clinical variants, and 15,823 procedure ratings.
• GigHz Imaging Protocol Library — A searchable library of 131 imaging protocols with the physics specs surfaced and the matching ACR Appropriateness Criteria alongside. Plain-English narratives readable in 60 seconds, organized by modality.
• GigHz Radiation Dose Calculator — Pick the imaging studies a patient has had and see total dose in millisieverts (mSv) with comparisons to natural background radiation, transatlantic flights, and chest X-rays. Useful for shared decision-making.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026